Cargando…

Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors

Detalles Bibliográficos
Autor principal:	Pasetto, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601717/ https://www.ncbi.nlm.nih.gov/pubmed/33007884 http://dx.doi.org/10.3390/cancers12102818

Ejemplares similares

Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
por: Mirzaei, Hamid R., et al.
Publicado: (2017)

Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
por: Mirzaei, Hamid R., et al.
Publicado: (2019)

Use of CD137 up-regulation to identify T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes
por: Parkhurst, Maria, et al.
Publicado: (2015)

The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy
por: Kye, Yae, et al.
Publicado: (2022)

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
por: Springuel, Lorraine, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for solid tumors
por: Newick, Kheng, et al.
Publicado: (2016)

New Chimeric Antigen Receptor Design for Solid Tumors
por: Wang, Yuedi, et al.
Publicado: (2017)

Supercharged chimeric antigen receptor T cells in solid tumors
por: Pant, Ayush, et al.
Publicado: (2022)

Chimeric antigen receptor T cells applied to solid tumors
por: Zhou, Zhongguo, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy and Ablative Therapies for Solid Tumors: Recent Advances and Clinical Applications
por: Zhu, Jing, et al.
Publicado: (2019)

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
por: Stock, Sophia, et al.
Publicado: (2022)

Victories and deceptions in tumor immunology: Stimuvax(®)
por: Kroemer, Guido, et al.
Publicado: (2013)

Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors
por: Saba, Nabil F., et al.
Publicado: (2012)

MST1R as a potential new target antigen of chimeric antigen receptor T cells to treat solid tumors
por: An, Wen, et al.
Publicado: (2023)

Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy
por: Nakagawa, Tomoyoshi, et al.
Publicado: (2022)

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
por: Kosti, Paris, et al.
Publicado: (2018)

Targeting ERBB2 mutations in solid tumors: biological and clinical implications
por: Cousin, Sophie, et al.
Publicado: (2018)

Identification of mutation-specific tumor infiltrating lymphocytes from metastatic ovarian cancer
por: Deniger, Drew C, et al.
Publicado: (2015)

Immunological targets for cancer therapy: new recognition
por: Shurin, Michael R
Publicado: (2018)

Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors
por: Jan, Chia-Ing, et al.
Publicado: (2021)

In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors
por: Sun, Zhichen, et al.
Publicado: (2022)

Immunotherapy for Solid Tumors
por: de Saint Basile, Hortense, et al.
Publicado: (2023)

Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review
por: Koucký, Vladimír, et al.
Publicado: (2019)

Prevention and treatment of cancers by tumor antigen-expressing Staphylococcus epidermidis
por: Kepp, Oliver, et al.
Publicado: (2023)

Clinical & Experimental Immunology: Highlights of 2021
por: Taams, Leonie S, et al.
Publicado: (2021)

Summary of the primer on tumor immunology and the biological therapy of cancer
por: Li, Yufeng, et al.
Publicado: (2009)

The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors
por: Rahma, Osama E, et al.
Publicado: (2014)

T Cells Immunology in the Immunological Diseases
por: Wu, Xiuli, et al.
Publicado: (2014)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
por: Guo, Yelei, et al.
Publicado: (2016)

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
por: Zhang, Erhao, et al.
Publicado: (2018)

Chimeric antigen receptor T cells: a novel therapy for solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future
por: Srour, Samer A., et al.
Publicado: (2022)

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors
por: Neeser, A., et al.
Publicado: (2023)

Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics
por: Magliacane, Gilda, et al.
Publicado: (2015)

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
por: Toomey, Sinead, et al.
Publicado: (2020)

Metastasis and Tumor Cell Migration of Solid Tumors
por: Hoeppner, Jens, et al.
Publicado: (2021)

Solid Tumors in Children and Adolescents
por: Lee, Jun Ah
Publicado: (2018)

Adoptively transferred tumor-infiltrating T cells target somatic cancer mutations in a human papillomavirus+ cancer patient with complete tumor regression
por: Stevanović, Sanja, et al.
Publicado: (2015)

Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin
por: Zhang, Zhijie, et al.
Publicado: (2023)

Cancer Immunology with a Focus on Understudied Cancers as Targets for Immunotherapy
por: Young, M. Rita I.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_35ghfsbmsgac3g0ql34n4s245a